October 2023 Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101, A Novel CDH17 CAR T Cell Therapy for Advanced Gastrointestinal Cancers
October 2023 Positive Preliminary Phase 1A Data For CLTX CAR T in Recurrent Brain Cancer Clinical Trial
June 2024 Chimeric Therapeutics (ASX:CHM) | Webinar with Dr Rebecca McQualter on Sharewise | 17/06/24
October 2023 CEO Jennifer Chow talks about Revolutionising Cancer Care with Cell Therapy on Kalkine Media Oct 2023